Finally, although these results do not support the addition of NEP inhibition to AT1R antagonism against experimental AngII-induced hypertension, atherosclerosis, or AAA formation, this drug combination may have benefit against other modes of inducing these cardiovascular diseases. Here, AGTR1 is linked to triple-A syndrome.